Plain-English translation of NCT04307576 on ClinicalTrials.gov ↗ · Source last updated · Translation generated · How we translate trials
Phase 3 — Testing in thousands of people, comparing the treatment against what doctors currently use. This is the last big step before approval.
ALLTogether1 is a large European treatment study for children and young adults (ages 0–45) newly diagnosed with acute lymphoblastic leukemia (ALL). The trial tests whether different combinations of chemotherapy drugs and targeted treatments like Inotuzumab and can achieve the same or better survival rates while causing fewer serious side effects than standard treatment.
Although survival rates for ALL are now quite good (around 92% in children), some patients still relapse and die from the disease, while others suffer lasting damage from treatment or develop secondary cancers. This trial aims to identify which patients truly need intensive therapy and which could do just as well with gentler approaches, personalizing care to each patient's specific disease characteristics.
You likely qualify if…
You likely don't qualify if…
Your participation will involve standard ALL chemotherapy treatment lasting about 2 years, with regular hospital visits for drug infusions, blood tests, and checkups. Depending on your specific disease characteristics and risk category, you may be randomly assigned to receive either standard chemotherapy or a modified version with one or more targeted medications (such as Inotuzumab or ) added to reduce relapses. Throughout treatment, you'll be closely monitored for effectiveness and side effects, with your treatment plan adjusted as needed based on how your leukemia responds.
AI-generated summary from trial data · Jul 3, 2026 · Not medical advice
Belgium